Who is sponsoring NCT03737955?

NCT03737955 is sponsored by University of Washington.

What drugs are being tested in NCT03737955?

Interventions in NCT03737955: Gemtuzumab Ozogamicin, Quality-of-Life Assessment.

What condition does NCT03737955 study?

NCT03737955 studies Acute Myeloid Leukemia.

Is NCT03737955 still recruiting?

NCT03737955 is currently recruiting now. Last updated 28 January 2026.

Last reviewed 2026-01-28 · How we verify

NCT03737955

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Recruiting now Phase 2 Last updated 28 January 2026

What this trial tests

Phase 2 trial testing Gemtuzumab Ozogamicin in Acute Myeloid Leukemia in 36 participants. Currently enrolling.

Timeline

30 November 2018

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	University of Washington
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	30 November 2018
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

Gemtuzumab Ozogamicin (Gemtuzumab Ozogamicin) — full drug profile →
Quality-of-Life Assessment

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →

Sponsor

University of Washington

Who can join

18 and older, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies the how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in patients with acute myeloid leukemia. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a chemotherapy drug, called ozogamicin. Gemtuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD33 receptors, and delivers a chemotherapy known as calicheamicin to kill them.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches.
Winer ES, Stone RM. · · 2019 · cited 92× · PMID 31321011 · DOI 10.1177/2040620719860645
Natural killer cell-based immunotherapy for acute myeloid leukemia.
Xu J, Niu T. · · 2020 · cited 83× · PMID 33287858 · DOI 10.1186/s13045-020-00996-x
New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise.
Bohl SR, Bullinger L, Rücker FG. · · 2019 · cited 56× · PMID 31018543 · DOI 10.3390/ijms20081983
Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats.
Williams BA, Law A, Hunyadkurti J, Desilets S, et al · · 2019 · cited 43× · PMID 31434267 · DOI 10.3390/jcm8081261
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL, Ravandi F, Patel KP, Short NJ. · · 2021 · cited 40× · PMID 34479626 · DOI 10.1186/s13045-021-01148-5
MRD Tailored Therapy in AML: What We Have Learned So Far.
Ngai LL, Kelder A, Janssen JJWM, Ossenkoppele GJ, et al · · 2020 · cited 37× · PMID 33575214 · DOI 10.3389/fonc.2020.603636
Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia.
Yu B, Liu D. · · 2019 · cited 37× · PMID 31695916 · DOI 10.1186/s40364-019-0175-x
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia.
Swaminathan M, Cortes JE. · · 2023 · cited 28× · PMID 36845850 · DOI 10.1177/20406207231154708

Verify or expand the search:

Other trials of Gemtuzumab Ozogamicin

Trials testing the same drug.

NCT06917911 — Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin · Phase 2 · not yet recruiting
NCT05564390 — MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi · Phase 2 · recruiting
NCT04915612 — Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patient · Phase 1 · completed
NCT04207190 — Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · completed
NCT04293562 — A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed A · Phase 3 · recruiting

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03737955 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 28 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03737955.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing